ABOS LongAcumen Pharmaceuticals, Inc. is gearing up for a big move, and it looks like it's about to break through some important levels. As the stock gets ready to cross a low volume node, we could see it shoot up toward higher targets. They’ve got some exciting news coming up, too—a late-breaking presentation at the CTAD conference from Oct. 29 to Nov. 1, where they’ll share how they’re screening participants for their Phase 2 trial of sabirnetug (ACU193), a treatment aimed at Alzheimer’s disease. This innovative approach is really promising, and with the data from the conference, we could see more interest in the stock. Keep an eye on ABOS; it might be a great time to get in! No time targets, shares only on my end, Good luck!
I also love to see targets like Target Maintained With a $15.00/Share by HC Wainwright & Co.
